987 related articles for article (PubMed ID: 16787254)
21. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.
Perrin MJ; Subbiah RN; Vandenberg JI; Hill AP
Prog Biophys Mol Biol; 2008; 98(2-3):137-48. PubMed ID: 19027781
[TBL] [Abstract][Full Text] [Related]
22. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels.
Lin C; Cvetanovic I; Ke X; Ranade V; Somberg J
Am J Ther; 2005; 12(4):328-36. PubMed ID: 16041196
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.
Stansfeld PJ; Sutcliffe MJ; Mitcheson JS
Expert Opin Drug Metab Toxicol; 2006 Feb; 2(1):81-94. PubMed ID: 16863470
[TBL] [Abstract][Full Text] [Related]
24. Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.
Dennis AT; Nassal D; Deschenes I; Thomas D; Ficker E
J Biol Chem; 2011 Sep; 286(39):34413-25. PubMed ID: 21832094
[TBL] [Abstract][Full Text] [Related]
25. Molecular basis and drug sensitivity of the delayed rectifier (IKr) in the fish heart.
Hassinen M; Haverinen J; Vornanen M
Comp Biochem Physiol C Toxicol Pharmacol; 2015; 176-177():44-51. PubMed ID: 26215639
[TBL] [Abstract][Full Text] [Related]
26. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Nogawa H; Kawai T
Eur J Pharmacol; 2014 Oct; 741():336-9. PubMed ID: 24998878
[TBL] [Abstract][Full Text] [Related]
27. Computational Models for Understanding of Structure, Function and Pharmacology of the Cardiac Potassium Channel Kv11.1 (hERG).
Wacker S; Noskov SY; Perissinotti LL
Curr Top Med Chem; 2017; 17(23):2681-2702. PubMed ID: 28413954
[TBL] [Abstract][Full Text] [Related]
28. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
29. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
30. Revealing the structural basis of action of hERG potassium channel activators and blockers.
Perry M; Sanguinetti M; Mitcheson J
J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767
[TBL] [Abstract][Full Text] [Related]
31. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Sanguinetti MC; Mitcheson JS
Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
34. hERG channel trafficking: novel targets in drug-induced long QT syndrome.
Dennis A; Wang L; Wan X; Ficker E
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1060-3. PubMed ID: 17956279
[TBL] [Abstract][Full Text] [Related]
35. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
Sanguinetti MC; Jiang C; Curran ME; Keating MT
Cell; 1995 Apr; 81(2):299-307. PubMed ID: 7736582
[TBL] [Abstract][Full Text] [Related]
36. Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.
Hong HK; Park MH; Lee BH; Jo SH
Biochem Biophys Res Commun; 2010 Apr; 394(3):536-41. PubMed ID: 20211602
[TBL] [Abstract][Full Text] [Related]
37. hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.
Staudacher I; Wang L; Wan X; Obers S; Wenzel W; Tristram F; Koschny R; Staudacher K; Kisselbach J; Koelsch P; Schweizer PA; Katus HA; Ficker E; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2011 Feb; 383(2):119-39. PubMed ID: 21120454
[TBL] [Abstract][Full Text] [Related]
38. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
De Bruin ML; Pettersson M; Meyboom RH; Hoes AW; Leufkens HG
Eur Heart J; 2005 Mar; 26(6):590-7. PubMed ID: 15637086
[TBL] [Abstract][Full Text] [Related]
39. Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, I(Kr), and the underlying hERG ion channel.
Thomas D; Kiehn J; Katus HA; Karle CA
Basic Res Cardiol; 2004 Jul; 99(4):279-87. PubMed ID: 15221346
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
